CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Candel Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.21+0.02 (+0.24%)
Close on Oct 19, 2026
- Market cap
- $608.62M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 111.9% | -64.6% | |
| Return on assets | – | – | -32.9% | |
| Current ratio | – | 7.46 | 13.49 | |
| Debt to equity | – | – | – | |
| Interest coverage | – | – | -22.8× | |
| Capex to revenue | – | 1180.8% | – | |
| Diluted shares | – | 12M | 53M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Candel Therapeutics generated $153.22M from operations and spent $4.19M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$153.22M
Used
$4.19M
Capital expenditure$4.19M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-15035.2%
×Asset turnover0.00×
×Equity multiplier1.49×
=Return on equity, FY2022-33.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -15035.2% | 0.00× | 1.49× | -33.6% |
| FY2021 | -28899.2% | 0.00× | 3.14× | -178.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$38.18M
- Cash generatingOperating cash flow above zero-$38.31M
- Return on assets improvedROA up on the prior year-133.9% → -35.7%
- Earnings backed by cashOperating cash flow above net income-$38.31M vs -$38.18M
- Less leverageLong-term debt to assets fell1.6% → –
- Better liquidityCurrent ratio rose2.77 → 13.49
- No dilutionShare count did not rise32M → 53M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –